Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

HJL Heerspink, A Karasik, M Thuresson… - The lancet Diabetes & …, 2020 - thelancet.com
Background Cardiovascular and kidney outcome trials have shown that sodium-glucose co-
transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with …
被引用次数：287 相关文章

[引用][C] Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

HJL Heerspink, A Karasik, M Thuresson… - The Lancet Diabetes & …, 2020 - cir.nii.ac.jp
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL
3): a multinational observational cohort study | CiNii Research CiNii 国立情報学研究所 学術 …

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.

HJL Heerspink, A Karasik, M Thuresson… - The lancet. Diabetes …, 2020 - europepmc.org
Background Cardiovascular and kidney outcome trials have shown that sodium-glucose co-
transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with …

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

HJL Heerspink, A Karasik… - … lancet. Diabetes & …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Cardiovascular and kidney outcome trials have shown that sodium-glucose co-
transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with …

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

HJL Heerspink, A Karasik… - The Lancet …, 2020 - keio.elsevierpure.com
Background: Cardiovascular and kidney outcome trials have shown that sodium-glucose co-
transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with …

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

HJL Heerspink, A Karasik, M Thuresson… - The Lancet Diabetes & …, 2020 - Elsevier
Background Cardiovascular and kidney outcome trials have shown that sodium-glucose co-
transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with …

[引用][C] Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

HJL Heerspink, A Karasik… - The Lancet …, 2020 - produccioncientifica.ucm.es
Background: Cardiovascular and kidney outcome trials have shown that sodium-glucose co-
transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with …

[引用][C] Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

HJL Heerspink, A Karasik… - The Lancet …, 2020 - produccioncientifica.ucm.es
Background: Cardiovascular and kidney outcome trials have shown that sodium-glucose co-
transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with …

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

HJL Heerspink, A Karasik… - The Lancet …, 2020 - keio.elsevierpure.com
Background: Cardiovascular and kidney outcome trials have shown that sodium-glucose co-
transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with …